Capsaicin patch license extension application withdrawn
21st March 2012
Astellas Pharma has withdrawn its application to the European Medicines Agency (EMA) for a license extension for Qutenza® (capsaicin 8% transdermal patch). The application was to extend the marketing authorization for Qutenza® to all adult patients with exclusion of patients with pain caused by diabetes.
The withdrawal was based on the Committee for Medicinal Products for Human Use (CHMP)'s view that the data provided would not allow the committee to conclude on a positive benefit-risk balance.
Qutenza® continues to be authorized for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults either alone or in combination with other medicinal products for pain.
- NICE: Care of dying adults in the last days of life quality standard
- Cochrane review: topical capsaicin (high concentration) for chronic neuropathic pain in adults
- Thalidomide updated SPC
- Scottish Medicines Consortium: Noqdirna
- NICE evidence summary: oral glycopyrronium bromide for severe sialorrhoea
- Cochrane review: pharmacological interventions for pruritus in adult palliative care patients
- Cochrane review: paracetamol with or without codeine or dihydrocodeine for neuropathic pain in adults
- Scottish Medicines Consortium: Butec patches for chronic non-malignant pain
- Glycopyrronium oral solution authorized for drooling now available in UK
- FDA approves 2mg naloxone nasal spray